<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168111">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01834599</url>
  </required_header>
  <id_info>
    <org_study_id>LoubertHMR2013/04</org_study_id>
    <nct_id>NCT01834599</nct_id>
  </id_info>
  <brief_title>Could the Cerebral Oximetry be a Good Technology to Measure Placental Oxygenation?</brief_title>
  <official_title>Could the Cerebral Oximetry (NIRS) be a Good Technology to Measure Placental Oxygenation in Pregnant Woman?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the potential of the cerebral oximeter to measure placental oxygenation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is general agreement among experts to recommend the use of phenylephrine as first line
      therapy for the treatment of arterial hypotension induced by spinal anaesthesia during
      caesarean delivery. In some studies, there are trends toward a lower PaO2 values in the
      umbilical cord venous blood when the mother receive this vasopressor. These findings may be
      a result of the vasoconstrictor effect of phenylephrine on utero-placental vessels, and a
      subsequent increased oxygen extraction by the fetus. The possibility to extract more oxygen
      would provide a certain &quot;safety margin&quot; in the event of compromised utero-placental blood
      flow during normal pregnancy. However, this &quot;safety margin&quot; should not be taken for granted
      in cases where signs of fetal distress are present, and this situation might influence the
      choice of vasopressors.

      It is well establish on a physiological basis that during labour, utero-placental blood flow
      is lower during the contractions. This lower blood flow could result in a lower saturation
      value measured by the cerebral oximeter.

      Twenty patients in labour will be included in this study. Patients will be recruited in
      obstetric clinic during pregnancy. Based on the second trimester ultrasound, two groups will
      be formed (anterior placenta group and posterior placenta group).

      During labour, once a functional epidural is in place, an Invos oximeter will be install.
      One sensor will be applied on the abdomen and the other on the forearm. Saturation values
      and timing of the contractions will be recorded for sixty minutes. Half of the recording
      will be done with an oxygen mask. Vitals signs will also be registered every five minutes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Difference between Δa and Δna</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Δa = For the anterior group, difference between the mean value area under the curve for the abdomen and arm; Δna= For the posterior group, difference between the mean value area under the curve for the abdomen and arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of the area under the curve of saturation with and without oxygen for each group</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Aa with Oxygen - Aa without oxygen; Ana with oxygen - Ana without oxygen</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Placental Oxygenation</condition>
  <arm_group>
    <arm_group_label>posterior placenta</arm_group_label>
    <description>cerebral oximetry device used to obtain: saturation value of the abdomen probe with no oxygen, saturation value of the abdomen probe with oxygen, saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen. Timing between the contractions measure by cardiotocography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anterior placenta</arm_group_label>
    <description>Cerebral oximetry device used to obtain: Saturation value of the abdomen probe with no oxygen, saturation value of the abdomen probe with oxygen, saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen. Timing between the contractions measure by cardiotocography</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cerebral oximetry</intervention_name>
    <description>tissue saturation measurement in pregnant women</description>
    <arm_group_label>posterior placenta</arm_group_label>
    <arm_group_label>anterior placenta</arm_group_label>
    <other_name>NIRS</other_name>
    <other_name>INVOS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        healthy pregnant woman at term gestation in labour
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy pregnant woman (ASA I or II)

          -  Term gestation ( &gt; 37 weeks)

          -  Normal pregnancy

          -  vaginal delivery

          -  obstetrical epidural in place

        Exclusion Criteria:

          -  patient refusal

          -  Any contraindication to neuraxial anesthesia

          -  cesarean section

          -  multiple gestation

          -  placentation abnormalities

          -  anormal placental perfusion

          -  Placental Abruption
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Loubert, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Loubert, MD, FRCPC</last_name>
    <phone>514-252-3426</phone>
    <email>loubertch@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louis-Philippe Fortier, MD, FRCPC</last_name>
    <phone>514-252-3426</phone>
    <email>lpfortier@mac.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maisonneuve Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Loubert, MD, FRCPC</last_name>
      <phone>514-252-3426</phone>
      <email>loubertch@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Louis-Philippe Fortier, MD, FRCPC</last_name>
      <phone>514-252-3426</phone>
      <email>lpfortier@mac.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Loubert, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Ouellette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis- Philippe Fortier, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Drolet, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Donati, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 15, 2013</lastchanged_date>
  <firstreceived_date>April 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Christian Loubert</investigator_full_name>
    <investigator_title>Christian Loubert, MD, FRCPC</investigator_title>
  </responsible_party>
  <keyword>placental oxygenation</keyword>
  <keyword>obstetric anesthesia</keyword>
  <keyword>NIRS</keyword>
  <keyword>cerebral oximetry</keyword>
  <keyword>cerebral oximeter</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
